Understanding how immune modulation affects tumor initiation in pancreatic cancer
Official title: Dissecting mechanisms of tumor initiation via immunomodulation
Funded at Clark Atlanta University · NIH-10784700 · Data updated 2026-11-12
This study is looking at how certain changes in a gene called Kras can lead to pancreatic cancer, with the goal of finding ways to detect it earlier and develop better treatments for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Clark Atlanta University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | March 17, 2021 |
| Project end | February 28, 2026 |
| Funding year | 2024 |
| Award (this year) | $308,000 |
| NIH project number | 5SC1GM140907-04 |
| Project ID | NIH-10784700 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals at high risk for pancreatic cancer, particularly those with a family history or genetic predisposition.
✕Less likely to help
Patients with advanced pancreatic cancer who are already diagnosed and have exhausted treatment options may not benefit from this research.
What this research studies
This research investigates the mechanisms behind the initiation of pancreatic cancer, particularly focusing on how mutations in the Kras gene influence the transformation of acinar cells into cancerous cells. By studying the acinar-to-ductal metaplasia (ADM) process, the research aims to uncover potential biomarkers for early detection and identify new drug targets for intervention. The approach involves analyzing the role of KrasG12D and KrasG12V mutations in the development of pancreatic ductal adenocarcinoma (PDAC) using transgenic mice and organoid models. Patients may benefit from advancements in early detection and treatment options stemming from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection and more effective treatment options for pancreatic cancer patients.
How similar studies have gone: Other research has shown promise in targeting Kras mutations and understanding the ADM process, indicating potential for success in this area.
Where this research is happening
-
Clark Atlanta University
Atlanta, United States Active
Researchers
- Principal investigator: Liou, Geou-Yarh — Clark Atlanta University
- Study coordinator: Liou, Geou-Yarh
Related research
Other NIH-funded projects on the same topics.
-
New drugs to overcome chemotherapy-resistant prostate cancer
Developing EED-blocking drugs to try to reverse chemotherapy resistance in men with advanced prostate cancer.
-
Recruiting top cancer researchers to tackle prostate cancer in Black men
A national center at Clark Atlanta University is funding hiring new faculty to advance understanding and prevention of prostate cancer health differences in male African-American communities.
-
Research Capacity Core for Cancer Research at Clark Atlanta University
A dedicated core at Clark Atlanta University helps prostate cancer researchers, especially in African American communities, access advanced lab services and training.
-
Investigator Development Core to Grow prostate cancer researchers
A support program helps early-career researchers in prostate cancer build their skills and launch new pilot projects.
-
YAP1 and SCML2 interaction in prostate cancer
Researchers are studying how two proteins, YAP1 and SCML2, work together in aggressive prostate cancer to understand why some forms resist therapy.
-
Epigenetic silencing of ID4 may drive stemness and resistant prostate cancer
A cancer research grant explores how turning off a protective gene (ID4) could make prostate cancer more stem-like and resistant to therapy, with potential patient impact.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.